Study: GLP-1 Access Gaps Widen Due to Insurance Cuts, Bias, Barriers

Access to weight-loss medications like semaglutide and tirzepatide remains deeply unequal, with new research from the Boston University School of Public Health showing that disparities in prescription rates have widened significantly since 2021.

While the percentage of eligible patients filling these prescriptions rose from 1.9% in 2021 to 16.6% in 2025, the benefits of these treatments are not reaching all populations equally, according to a study published in Health Affairs Scholar.

The analysis of more than 512,000 commercially insured patients found that prescriptions were consistently lower among men, Black and Hispanic patients, and those living in neighborhoods with lower socioeconomic status. "We have better treatments for obesity than ever, but access to them hasn’t caught up," said Dr. Andrew Stokes, senior author of the study and an associate professor of global health at BUSPH.

Employer Coverage and Medicaid Shifts

The difficulty in obtaining these drugs is compounded by changing insurance policies. According to data from Newser, a Business Group on Health study revealed that the portion of large corporations providing GLP-1 coverage for weight management fell from 72% in 2025 to 60% this year. No companies among the 127 surveyed plan to add the benefit this year, citing rising health costs as a primary driver for the cuts.

Public insurance programs are also seeing sharp declines in access. A separate study published in JAMA found that Medicaid-reimbursed prescriptions for weight-loss-approved GLP-1s fell by approximately 84% in four states—California, New Hampshire, Pennsylvania, and South Carolina—after those states withdrew coverage on Jan. 1, 2026.

Dropped GLP-1 Coverage Leaves Workers
Photo: Newser
State Action Prescription Rate Change
States withdrawing Medicaid coverage 84% decrease
States maintaining Medicaid coverage Modest decline

Administrative Burdens and Systemic Barriers

The disparities in access are not solely due to insurance status, as the BUSPH researchers observed persistent gaps even among those with commercial insurance.

Dr. Minh Trung Le, the study’s lead author, said that administrative barriers play a significant role in who receives treatment. "We need to look at how drug benefits are designed, including prior authorization, step therapy and out-of-pocket costs that land unevenly on different patients," Le told Medical Xpress.

Experts suggest that the current system often views obesity as a lifestyle failure rather than a chronic disease, which influences how providers and insurers approach coverage.

“These important results show how emerging patterns of GLP-1 access reflect the inequity and fragmentation of our overall health care system, where access to affordable care is all too often a function of where you work, what state you live in or how much money you have,” Dr. Katherine Hempstead, a senior policy officer at the Robert Wood Johnson Foundation, said.

Hempstead remarked to Medical Xpress that the system’s shortsighted nature and flawed incentives result in the loss of significant population health advantages.

Study: GLP-1 Access Gaps Widen Due to Insurance Cuts, Bias, Barriers
Photo: News-Medical

Common Questions About GLP-1 Accessibility

Why are prescription rates lower for Black and Hispanic patients?
Structural barriers, including systemic bias in healthcare, mistrust of the medical system, and higher medication costs, contribute to these disparities. Researchers found these gaps persisted even among commercially insured patients, highlighting long-standing inequities.

What happens to patients when Medicaid coverage is withdrawn?
Data from the JAMA study indicates that when coverage is removed, prescriptions drop almost immediately. Researchers said that patients in states that withdrew coverage saw a sharp decline from 2,914 to 421 prescriptions per 100,000 beneficiaries between the end of 2025 and the first quarter of 2026.

Are these drugs considered standard benefits?
No, obesity treatment is not a standard benefit on most health insurance policies. Dr. Angela Fitch, a physician specializing in obesity care, told Endocrinology Advisor that despite the American Medical Association declaring obesity a disease in 2013, the condition is often still viewed as a "cosmetic" issue by payers.

The Boston University School of Public Health was established in 1976 as a program for working medical professionals, originally requiring students to attend night classes on Tuesdays, Wednesdays, and Thursdays. It officially became a school of the university in 1979 and has since grown to support a research portfolio valued at more than $180 million.

The investigators said that their analysis could not evaluate health outcomes or private GLP-1 payments, meaning the substantial reduction in Medicaid-supported prescriptions does not confirm that every patient impacted by the change discontinued their regimen.